Cancer Biomarkers Market 12.2% CAGR to 2022 Led by North America

Wednesday, October 11, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, October 11, 2017 /PRNewswire/ --

The global cancer biomarkers market is forecast to reach $20.48

billion by 2022 from $11.53 billion in 2017 at a CAGR of 12.2% during (2017-2022) driven by the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D
funding from government and private bodies, and rising demand for personalized medicine in cancer therapies according to

Browse 268 Market Data Tables and 37 Figures spread through 267 Pages and in-depth TOC on "Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022" .

The major players in cancer biomarkers market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).

The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.

Make an Inquiry on Cancer Biomarkers Market Global Forecast to 2022 research report at .

North America is expected to dominate the cancer biomarkers market and APAC growing at the highest CAGR. North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.

On the basis of biomarker type, the cancer biomarkers market segmented into protein biomarker, genetic biomarker, and other biomarkers. Protein biomarkers estimated to account for the largest market share in 2016. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.

Inquire for Discount on "Cancer Biomarkers Market Global Forecast to 2022" research report at .

Break of primary participants was as mentioned below:

  • By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3-30%
  • By Designation: Director level-18%, C-Level-27%, and Others-55%
  • By Region: North America-50%, Europe-20%, Asia-Pacific-20%, and RoW-10%

The cancer biomarkers market research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output to remain successful.

Another research titled Biomarkers Market Global Forecast to 2021 says, the global biomarkers market is estimated to reach $53.34 billion by 2021 from $27.95 billion in 2016, at a CAGR of 13.8% from 2016 to 2021. The consumables segment is estimated to account for the largest share of the global biomarkers market in 2016. The safety biomarkers segment is estimated to account for the largest share in 2016. The diagnostics segment is estimated to account for the largest share of the market in 2016. The cancer segment is estimated to account for the largest share of the biomarkers market in 2016. Companies such as QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S.) have been profiled in this 157 pages research report available at .

Explore more reports on Biotechnology Market at .

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact: Hrishikesh Patwardhan 2nd Floor, Metropole Building, Next to Inox Theatre, Bund Garden Road, Pune - 411001. Maharashtra, India. +1-888-391-5441

Connect with Us:

G+ / Google Plus:



RSS / Feeds:

SOURCE RnRMarketResearch

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store